29Jul
27Jul
High-tech brace allows Mechanicsburg teen use left arm again
Dees is the first adolescent worldwide to use the MyoPro 2 — a powered arm brace designed to restore movement to paralyzed or weakened arms — out of trials, according to Jonathan Naft, vice president of Myomo, a medical robotics company based in Cambridge, Massachusetts, that takes it names from “my own motion.” Read more >>
26Jul
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis (“DM”). Dermatomyositis is a rare and serious multisystem inflammatory autoimmune disease affecting muscle and skin. The U.S. Food and Drug Administration (“FDA”) provided guidance on the overall study design of this trial at a recent end-of-Phase 2 meeting....
24Jul
With New Branding and Strategy, Premama Targets Millennial Moms
Consumers are looking to niche, distinctly branded wellness products for everything from their heart and gut health, to their skin and hair care. With a new look, reformulated products and new offerings, female-focused nutrition company Premama is hoping women shoppers will consider how their diets can impact the many stages of motherhood, too. Read more >>
24Jul
Guide: 12 Boston Startups That Tackle the $1.3 Trillion Student Debt Problem
MIT grad Laurel Taylor created FutureFuel in Boston to tackle two problems: the need for students to pay off debt and the need for employers to hire qualified STEM talent (which currently has a huge shortage). Read more >>
21Jul
Johns Hopkins spinout Neuraly launches with $36M funding round
The Maryland biotech startup is developing new treatments for Parkinson's disease and Alzheimer’s disease. Read more >>
21Jul
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Read more >>
19Jul
Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease
Today, Neuraly announced its launch to pioneer the development of disease-modifying agents for neurodegenerative disorders. Read more >>
14Jul
Announcing the 2018 BostonFest Coolest Companies Finalists
Finalists for this year’s Coolest Companies, BostInno's signature competition at BostonFest, include Wasabi. Read more >>
11Jul